OC
FPRX

Oppenheimer & Co’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Oppenheimer & Co’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,440
Closed -$223K – 1381
2017
Q3 		$223K Buy
+5,440
New +$171K 0.01% 1149
2017
Q1 		– Sell
-10,957
Closed -$549K – 1370
2016
Q4 		$549K Sell
10,957
-453
-4% -$23.8K 0.02% 778
2016
Q3 		$599K Sell
11,410
-215
-2% -$10.3K 0.02% 747
2016
Q2 		$481K Sell
11,625
-1,352
-10% -$58.8K 0.01% 805
2016
Q1 		$527K Sell
12,977
-6,495
-33% -$223K 0.02% 733
2015
Q4 		$808K Sell
19,472
-30,482
-61% -$1.02M 0.02% 623
2015
Q3 		$769K Buy
49,954
+6,451
+15% +$139K 0.02% 665
2015
Q2 		$1.08M Buy
+43,503
New +$969K 0.03% 603

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Oppenheimer & Co's FPRX Position: Q4 2017 in Review

Oppenheimer & Co sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 5,440 shares — an estimated $223K sold.

Oppenheimer & Co first reported a position in FPRX in Q2 2015 and held it in 8 quarters. The position peaked at $1.08M in Q2 2015. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • Oppenheimer & Co reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Oppenheimer & Co sold 5,440 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $223K.
  • Oppenheimer & Co first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 8 quarters.
  • Oppenheimer & Co's Five Prime Therapeutics, Inc. position peaked at $1.08M in Q2 2015.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Oppenheimer & Co's 13F filing for Q4 2017, filed 7 Feb 2018.